Ezurpimtrostat
Term · Oncology and biomedicine · MLC-T-ONC-013504
An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.
| Identifier | MLC-T-ONC-013504 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | NCIt PT SLCT inhibitor GNS561; SLCT inhibitor GNS561 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013504",
"term": "Ezurpimtrostat",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.",
"synonyms": [
"NCIt PT SLCT inhibitor GNS561",
"SLCT inhibitor GNS561"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/ezurpimtrostat/"
}
Record 7,099 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.